After performing the univariate analysis and identifying statistically significant variables, we conducted a multivariate analysis (Table 8), identifying dyslipidemia, age 72 years or older, previous cardiovascular disease, and basal NT-proBNP as risk factors for cardiotoxicity in patients receiving treatment with anthracyclines as a first-line treatment for lymphoma. This evidence concerns the gene NPPB and metabolic syndrome.